Vir Biotechnology, Inc. (VIR)

Name: Vir Biotechnology, Inc. (VIR) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001706431 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Vir Biotechnology, Inc. reported revenue of $68.56M. Revenue fell 7.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $303.23M.

Key ratios (year ended 2025-12-31)

-699.2%

Operating margin

-638.9%

Net margin

-57.2%

Return on year-end equity

-7.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-14

Headquarters locality: San Francisco · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Revenue	$303.23M	$68.56M	$74.20M	$86.18M	$1.62B	$1.10B	$76.37M	$8.09M	$10.67M	$2.71M
Cost of Revenue	$15.0K	$26.0K	$845.0K	$2.77M	$146.32M	$65.86M	$0	$0	n/a	n/a
Gross Profit (computed)	n/a	n/a	n/a	n/a	$1.47B	$1.03B	n/a	n/a	n/a	n/a
R&D Expense	$484.02M	$455.97M	$506.50M	$579.72M	$474.65M	$448.01M	$302.41M	$148.47M	$100.23M	$62.51M
Operating Income	-$280.19M	-$479.33M	-$587.16M	-$684.30M	$833.07M	$420.75M	-$296.98M	-$177.98M	-$118.69M	-$81.50M
Depreciation & Amortization	$11.51M	$11.68M	$14.56M	$19.45M	$6.78M	$5.28M	$4.40M	$3.29M	$1.62M	$255.0K
EBITDA	-$268.68M	-$467.65M	-$572.61M	-$664.85M	$839.85M	$426.03M	-$292.58M	-$174.69M	-$117.07M	-$81.24M
Net Income	-$251.68M	-$437.99M	-$521.96M	-$615.06M	$515.84M	$528.58M	-$298.67M	-$174.68M	-$115.88M	-$69.85M
EPS (Diluted)	n/a	-$3.16	-$3.83	-$4.59	$3.83	$3.96	-$2.51	-$5.76	n/a	n/a
Total Assets	$1.21B	$1.00B	$1.40B	$1.92B	$2.80B	$1.95B	$918.76M	$512.07M	$191.60M	n/a
Total Liabilities	$232.31M	$237.55M	$248.43M	$328.82M	$724.12M	$522.42M	$201.91M	$88.13M	$61.64M	n/a
Shareholders' Equity	$982.49M	$765.28M	$1.15B	$1.59B	$2.08B	$1.43B	$716.85M	$423.94M	-$179.18M	-$68.92M
Cash & Equivalents	$278.73M	$232.19M	$222.95M	$241.58M	$848.63M	$347.81M	$436.57M	$109.33M	$47.60M	$187.92M
Operating Cash Flow	-$202.51M	-$391.78M	-$446.35M	-$778.78M	$1.66B	-$47.59M	-$190.94M	-$129.63M	-$94.10M	-$66.38M
Capital Expenditures	$1.09M	$4.83M	$7.30M	$21.57M	$68.01M	$21.82M	$6.55M	$8.94M	$8.19M	$2.74M
Free Cash Flow	-$203.59M	-$396.61M	-$453.65M	-$800.36M	$1.60B	-$69.41M	-$197.49M	-$138.57M	-$102.29M	-$69.12M
Shares Outstanding	169.19M	139.47M	136.96M	134.78M	133.24M	131.16M	127.42M	107.65M	8.86M	n/a
Weighted Average Diluted Shares	n/a	138.52M	136.25M	134.13M	134.81M	133.44M	119.16M	30.35M	n/a	n/a
EPS (Basic)	n/a	-$3.16	-$3.83	-$4.59	$3.89	$4.07	-$2.51	-$5.76	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView